Promote project cooperation,building an efficient docking platform; Discuss the forefront of policy, focusing on technological innovation hot issues
ENMORE HEALTHCARE, an independent business unit of ENMORE BIZ, has been engaging in IVD, antibody drug, immunotherapy, vaccine, plasma and other healthcare industries since 2008. It provides industry events, executive search and media promotion service. ENMORE HEALTHCARE is committed to build the service platform of a focus on life sciences and healthcare fields, enhance mutual understanding of international and domestic counterparts, to promote cooperation between enterprises, scientific research and medical institutions, to enhance the communication between the government, association and enterprise.
With China gradually entering the aging society, China's healthcare industry has developed into a market of nearly 4 trillion RMB. The market maintained a compound annual growth rate of over 20% in the past five years and is expected to double its size in next five years, which will reach 8 trillion RMB. By then, it will occupy the proportion of 10% of China's GDP. Healthcare industry is attracting more and more attention.
Mergers and acquisitions of Chinese healthcare industry surged in 2015, and both the number and amount of mergers & acquisitions have hit a new high. Some large pharmaceutical companies, especially listed companies are committed to completing the layout of the whole industry chain and accelerating the pace of mergers & acquisitions in order to expand the market size. Some segments such as precision medicine, online medical services and gene sequencing are especially popular. At the same time, Chinese enterprises are also actively looking for overseas mergers & acquisitions opportunities, including medical equipment, medical services, as well as biological technology and other fields.
On February 27, 2016, Enmore Biopharm Conference (EBC) was held in Nanjing and attracted the participation of many investment institutions dedicated in healthcare field. This October, Enmore Healthcare will focus more on the docking demands of medical enterprises and investment institutions, thus the Enmore Healthcare Industry Investment Conference 2016 will be held, inviting China's most high-end and innovative medical start-up companies, medical corporate executives with financing needs and the most professional investment decision makers gathering together, to promote the depth of cooperation between the industry and capital, building a platform to promote the healthy development of the medical enterprises.
[Exclusive] 20/30-minute keynote speech during the main session
20/30-minute keynote speech during conference tracks
Sponsor logo will be printed on the conference handbag
Sponsor logo will be printed on the conference lanyard
Sponsor logo will be printed on the conference stationery
Sponsor logo will be printed on the drinking water
Colored one page advertisement printed on conference proceeding
Titled Coffee Break
Sponsor logo will be showed during the titled coffee break
Presenting your service and products to attendees via poster
Provide the service of titled E-salon, online promotion, media reports and interviews
Cai Jiangnan, Director of Health management and policy research center, CEIBS
Hua Ping, Managing Partner, SBCVC
Lu Gang, Managing Director, Legend Star
Mark Winnett, Early Development Portfolio Leader, Johnson & Johnson
Zhu Zhongyuan, Partner, WuXi Healthcare Ventures
Yu Guoliang, Venture Partner, OrbiMed Healthcare Fund Management
Yang Zhi, Chairman, BVCF
Chen Shaoyu, Partner, Covington & Burling LLP
Zhu Yaoyi, VP, FOSUNPHARMA
Zhao Lijian, CMO, BGI
Jiang Tang, VP, Dian Diagnostics
Sun Hongye, CTO, WuXiNextCODE
Wu Mingyuan, President, VCANBIO Cell & Gene Engineering Corporation, Ltd
Zhou Xinhua, CEO, Genor Biopharma
Chen Zhisheng, CEO, WuXi Biologics
Luo Lvsong, Head, Discovery Biology, BeiGene